We & Win Diversification Co (4113) Fair Value & Analysis
Industrials · TW · Market cap 3.9B TWD
Fair value as of: Jul 11, 2026
From 4 valuation models · updated today
Fair value updated Jul 11, 2026 — revised from 83.07 TWD to 14.87 TWD (−82.1%) since Jun 24, 2026. Share price −1.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 14.20 TWD – 26.05 TWD · fair‑value band 7.47 TWD – 22.52 TWD · the 15.00 TWD price screens above the 14.87 TWD fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
We & Win Diversification Co (4113) currently trades at 15.00 TWD, while our model-based Fair Value estimate is 14.87 TWD — implying the stock looks roughly 0.9% overvalued today. We read business quality at 28/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 159M TWD. It earns a return on equity of -3.8%. Net debt stands at 9.7B TWD. Fundamentals as of Jul 11, 2026
Our scenario range runs from 7.47 TWD (bear case) to 22.52 TWD (bull case); at 15.00 TWD, the current price sits within that range. The share trades about 44% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -27% fair-value upside — at -1%, 4113 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
We & Win Diversification Co., Ltd. engages in the rental and sale of real estate properties in Taiwan. It is also involved in the public facilities construction investment; new towns and community development; wholesale of medical equipment; and international trade businesses. The company was formerly known as Oncoprobe Biotech Inc. and changed its name to We & Win Diversification Co., Ltd. in 2009. We & Win Diversification Co., Ltd. was founded in 1987 and is based in Kaohsiung, Taiwan.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
We & Win Diversification Co reported revenue of 610M TWD in FY2025 versus 1.4B TWD in FY2021, a compound −19.3%/yr. Reported net income was −100M TWD in FY2025.
Is 4113 fairly valued? → Check now
Similar stocks
10 more Engineering & Construction stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Larsen & Toubro Limited LTOD | $0.4110 | $0.0100 | -98% |
| Samsung C&T Corporation 028260 | 520,000 KRW | 268,469 KRW | -48% |
| China State Construction Engineering Corporation 601668 | ¥4.65 | ¥17.35 | +273% |
| TopBuild Corp BLD | 7,547 MXN | 3,472 MXN | -54% |
| Hyundai Engineering & Construction Co 000720 | 130,300 KRW | 55,602 KRW | -57% |
| United Integrated Services Co 2404 | 1,195 TWD | 1,681 TWD | +41% |
| Samsung E&A Co 028050 | 47,300 KRW | 34,365 KRW | -27% |
| Daewoo Engineering & Construction Co 047040 | 21,750 KRW | 18,915 KRW | -13% |
| L&K Engineering Co 6139 | 791.00 TWD | 782.96 TWD | -1% |
| Rail Vikas Nigam Limited RVNL | ₹235.61 | ₹14.53 | -94% |
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is We & Win Diversification Co (4113) undervalued?
What is the fair value of 4113?
What is the quality score of 4113?
What is the revenue of We & Win Diversification Co (4113)?
What is the net profit margin of 4113?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
The 25 strongest value stocks, free every month
Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.